Oramed Pharmaceuticals
ORMP
47 hedge funds and large institutions have $24.3M invested in Oramed Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 5 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
49% more capital invested
Capital invested by funds: $16.3M → $24.3M (+$8M)
4.71% more ownership
Funds ownership: 17.75% → 22.46% (+4.7%)
0% more funds holding
Funds holding: 47 → 47 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$241K |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$186K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$53.9K |
| 4 |
BlackRock
New York
|
+$53.4K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$52.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$191K |
| 2 |
State Street
Boston,
Massachusetts
|
-$150K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$97.5K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$71.2K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$42.9K |
ORMP Hedge Fund Activity: Q3 2025 in Review
47 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2025, worth a combined $24.3M — up 49% from $16.3M a quarter earlier.
Fund positioning in ORMP was balanced in Q3 2025: 5 funds opened new positions, 5 closed out, 9 added to existing stakes and 10 trimmed.
The largest buyer was Wells Fargo, adding an estimated $241K. The largest seller was Peapod Lane Capital, exiting entirely with an estimated $191K sold.
- 47 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $24.3M of Oramed Pharmaceuticals stock for Q3 2025, up 49% quarter-over-quarter.
- 5 funds opened new Oramed Pharmaceuticals positions in Q3 2025 and 5 closed out, a net change of 0 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2025 was Wells Fargo, an estimated $241K added.
- The largest Oramed Pharmaceuticals seller in Q3 2025 was Peapod Lane Capital, an estimated $191K sold.
Based on aggregated 13F filings for Q3 2025.